124 related articles for article (PubMed ID: 27789587)
1. Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk.
Shidfar A; Costa FF; Scholtens D; Bischof JM; Sullivan ME; Ivancic DZ; Vanin EF; Soares MB; Wang J; Khan SA
Cancer Prev Res (Phila); 2017 Jan; 10(1):89-97. PubMed ID: 27789587
[TBL] [Abstract][Full Text] [Related]
2. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
[TBL] [Abstract][Full Text] [Related]
5. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort.
Godfrey AC; Xu Z; Weinberg CR; Getts RC; Wade PA; DeRoo LA; Sandler DP; Taylor JA
Breast Cancer Res; 2013 May; 15(3):R42. PubMed ID: 23705859
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
Wang J; Shidfar A; Ivancic D; Ranjan M; Liu L; Choi MR; Parimi V; Gursel DB; Sullivan ME; Najor MS; Abukhdeir AM; Scholtens D; Khan SA
Int J Cancer; 2017 Jun; 140(11):2484-2497. PubMed ID: 28263391
[TBL] [Abstract][Full Text] [Related]
8. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).
Kim SY; Kawaguchi T; Yan L; Young J; Qi Q; Takabe K
Ann Surg Oncol; 2017 Oct; 24(10):2943-2949. PubMed ID: 28766230
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.
van Schooneveld E; Wouters MC; Van der Auwera I; Peeters DJ; Wildiers H; Van Dam PA; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Feb; 14(1):R34. PubMed ID: 22353773
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer.
Nair MG; Mavatkar AD; Naidu CM; V P S; C E A; Rajarajan S; Sahoo S; Mohan G; Jaikumar VS; Ramesh RS; B S S; Jolly MK; Maliekal TT; Prabhu JS
Cells; 2024 May; 13(10):. PubMed ID: 38786043
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.
Liu WH; Yeh SH; Lu CC; Yu SL; Chen HY; Lin CY; Chen DS; Chen PJ
Gastroenterology; 2009 Feb; 136(2):683-93. PubMed ID: 19027010
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
16. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
17. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
[TBL] [Abstract][Full Text] [Related]
19. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
[TBL] [Abstract][Full Text] [Related]
20. MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
Cizeron-Clairac G; Lallemand F; Vacher S; Lidereau R; Bieche I; Callens C
BMC Cancer; 2015 Jul; 15():499. PubMed ID: 26141719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
